A Physiologic Comparison of Two Approaches to Treating Peripheral Neuropathy

Part of paid clinical trials in Loma Linda, California.

Sponsor
Loma Linda University
Study ID
NCT05577390
Status
Recruiting

Conditions

  • Peripheral Neuropathy With Type 2 Diabetes

Eligibility Criteria

Sex
ALL
Age
45 Years - 85 Years
Healthy Volunteers
Not accepted

Interventions

  • Intraneural Facilitation Therapy Treatment — OTHER
    Intraneural Facilitation Therapy uses three manual holds to bias blood flow to closed endoneurial capillaries. The first is the facilitation hold, which is thought to pressurize the nervous system and bias circulation from the artery into the epineurium. This hold stretches the nerve further than the artery, increasing the amount of elastin in the artery and enlarging the opening of the arterial junction increasing blood into the epineurium. The secondary hold then increases epineurial blood into the transperineurial vessels increasing pressure into the endoneurial capillaries of the site being treated. The third hold, known as the sub hold, encourages blood flow through ischemic endoneurial capillaries that have increased resistance/pressure through the application of Bernoulli's principle. The series of stretches will be repeated on the affected side for the treatment duration.
  • Standard Physical Therapy Treatment — OTHER
    The standard physical therapy treatment includes muscle stretching, balance, and strengthening exercises known to improve neuropathy symptoms.

Study Details

Diabetic peripheral neuropathy is one of the most common and costly microvascular complications of diabetes impacting more than 50% of patients and costing more than 10.1 billion dollars annually. Intraneural Facilitation Therapy (INF® Therapy) is a non-invasive technique that has shown to improve balance and pain in patients with Type 2 Diabetic Peripheral Neuropathy (T2DPN); however, the underlying physiological mechanisms need further understanding. The purpose of this study is to investigate the physiological mechanisms behind two approaches to treating T2DPN, INF® Therapy and standard physical therapy. Eligible subjects presenting with diabetic neuropathy symptoms will be recruited and referred to the Loma Linda University Health's Neuropathic Therapy Center. Forty patients will be evenly randomized into two groups: an INF® Therapy Treatment group and standard physical therapy treatment group. Subjects will participate in 11 study visits over a period of 6 weeks. Non-invasive assessments will measure neuropathy pain, heart rate variability, neuropathy severity, blood oxygen levels, and blood flow under the skin. Lab draws will measure inflammation levels in the blood and how well blood sugar levels have been maintained over a period of about 3 months. Descriptive statistics and repeated measures ANOVA will be used to analyze data and answer the research questions. The findings of this study will provide a better understanding of how INF® Therapy and standard physical therapy work, subsequently improving non-invasive treatment methods for T2DPN patients.

Key Dates

Start date
Jan 8, 2024
Status verified
Nov 2025
Primary completion
Aug 1, 2027
Completion
Aug 1, 2027

Study Design

Enrollment
40 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Intraneural Facilitation Therapy Treatment Group
    Subjects will receive nine 60-minute INF® Therapy Treatments during sessions 2 through 10. INF® Therapy is a non-invasive treatment that helps eliminate pain, tingling, numbness, and other symptoms that come with neuropathy.
  • Experimental: Standard Physical Therapy Treatment Group
    Subjects will receive nine 60-minute standard physical therapy treatments during sessions 2 through 10.

Primary Outcome Measure

The Impact of INF® Therapy and Standard Physical Therapy on Heart Rate Variability [ Time Frame: Through study completion, an average of 6 weeks. ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Loma Linda University Health Neuropathic Therapy CenterLoma LindaCalifornia92350
Mark Bussell, DPT, OCS
909-558-6799
Mark Bussell, DPT, OCS (PRINCIPAL_INVESTIGATOR)

Find similar trials in Loma Linda, CA

Related Studies